TACI/TNFRSF13B/CVID Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 0.2 mg/ml

TACI/TNFRSF13B/CVID Antibody Blocking Peptide Summary

• Description: A blocking peptide containing 15 amino amino terminus of human TACI.

  Source: Synthetic

  (Accession #: NP_036584)

• Source: Synthetic
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: TNFRSF13B
• Purity: N/A

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP1-76779.
  
  For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin.
• Preservative: 0.02% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: N/A

Alternate Names for TACI/TNFRSF13B/CVID Antibody Blocking Peptide

• CD267 antigen
• CD267
• CVID
• CVID2
• FLJ39942
• MGC133214
• TACI
• TACIMGC39952
• TNFRSF13B
• TNFRSF14B
• Transmembrane activator and CAML interactor
• tumor necrosis factor receptor 13B
• tumor necrosis factor receptor superfamily member 13B
• tumor necrosis factor receptor superfamily, member 13B

Background

TACI is a lymphocyte specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein binds to both APRIL and BAFF and induces activation of the transcription factors NFAT (nuclear-factor of activated T cells), AP1, and NF kappa B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith Magenis syndrome region on chromosome 17.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: TNFRSF13B